ArticleCancer cell international2025
SLC9A9 links tumor immune infiltration to therapeutic response in colorectal cancer with emphasis on mismatch repair proficient subtype.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundImmunotherapy has revolutionized colorectal cancer (CRC) treatment, however, predictive biomarkers for mismatch repair proficient (pMMR) tumors remain scarce. The involvement of the SLC9A9 (solute carrier family 9 member A9) gene in the tumor immune microenvironment is poorly understood.
methodsWe analyzed publicly available gene expression datasets to assess SLC9A9 expression levels in CRC patients. The relationships between SLC9A9 expression and lymphocyte infiltration, specifically CD8 + and CD4 + T cells, were examined using correlation and regression analyses.
resultsExpression of SLC9A9 was notably higher in normal CRC tissues compared to the adjacent tumor tissues, particularly among pMMR CRC patients. Moreover, a significant association was found between SLC9A9 expression and lymphocyte infiltration in these pMMR patients. Interestingly, pMMR patients exhibiting high SLC9A9 expression showed enhanced sensitivity to immunotherapy compared to their counterparts with low SLC9A9 expression.
conclusionsOur study highlights the prognostic value of SLC9A9 in pMMR CRC and its correlation with lymphocyte infiltration, particularly CD8 + and CD4 + T cells. These results provide a foundation for further investigation into the mechanistic link between SLC9A9 expression and tumor immunity, potentially facilitating the creation of innovative therapeutic approaches for pMMR CRC patients. Collectively, SLC9A9 may serve as a novel immune checkpoint to assess the efficacy of immunotherapy and predict therapeutic outcomes in pMMR CRC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.